sb 203580 has been researched along with nafenopin in 1 studies
| Studies (sb 203580) | Trials (sb 203580) | Recent Studies (post-2010) (sb 203580) | Studies (nafenopin) | Trials (nafenopin) | Recent Studies (post-2010) (nafenopin) |
|---|---|---|---|---|---|
| 3,489 | 4 | 1,137 | 227 | 2 | 3 |
| Protein | Taxonomy | sb 203580 (IC50) | nafenopin (IC50) |
|---|---|---|---|
| Mitogen-activated protein kinase 1 | Homo sapiens (human) | 0.8151 | |
| Mitogen-activated protein kinase 14 | Homo sapiens (human) | 3.7405 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cosulich, S; James, N; Roberts, R | 1 |
1 other study(ies) available for sb 203580 and nafenopin
| Article | Year |
|---|---|
Role of MAP kinase signalling pathways in the mode of action of peroxisome proliferators.
Topics: Animals; Apoptosis; Cells, Cultured; Imidazoles; MAP Kinase Signaling System; Mitogen-Activated Protein Kinases; Nafenopin; p38 Mitogen-Activated Protein Kinases; Palmitoyl Coenzyme A; Peroxisome Proliferators; Pyridines; Rats; S Phase; Tumor Necrosis Factor-alpha | 2000 |